{"id":"rosuvastatin-omeprazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rosuvastatin is a statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby lowering LDL cholesterol and reducing cardiovascular risk. Omeprazole is a proton pump inhibitor that suppresses gastric acid production, protecting against acid-related GI injury that may occur with statin therapy or in patients at risk for ulcers. The combination addresses both lipid management and GI protection in a single formulation.","oneSentence":"This combination drug reduces cholesterol via HMG-CoA reductase inhibition (rosuvastatin) while simultaneously reducing gastric acid secretion (omeprazole) to protect the gastrointestinal tract.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:06:15.722Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia with elevated cardiovascular risk in patients requiring gastric acid suppression"}]},"trialDetails":[{"nctId":"NCT07223671","phase":"PHASE1","title":"Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-12-31","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT02592317","phase":"PHASE1","title":"A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2016-02-12","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":23},{"nctId":"NCT07235748","phase":"PHASE1","title":"Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier (I.R.I.S.)","startDate":"2025-10-07","conditions":"Healthy Adult Participants","enrollment":28},{"nctId":"NCT07269756","phase":"PHASE1","title":"A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2025-12-08","conditions":"Obesity, Overweight","enrollment":40},{"nctId":"NCT05444556","phase":"PHASE1","title":"A Study of Imlunestrant (LY3484356) in Female Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-07-07","conditions":"Healthy","enrollment":113},{"nctId":"NCT06975605","phase":"PHASE1","title":"Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs.","status":"COMPLETED","sponsor":"GRIN Therapeutics, Inc.","startDate":"2025-05-20","conditions":"Tuberous Sclerosis Complex (TSC), Focal Cortical Dysplasia, Other Neurological Disorders","enrollment":18},{"nctId":"NCT06949124","phase":"PHASE1","title":"A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-04-28","conditions":"Endometriosis, Uterine Fibroids, Assisted Reproduction","enrollment":20},{"nctId":"NCT06279234","phase":"PHASE1","title":"A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-02-20","conditions":"Type 2 Diabetes Mellitus (T2DM), Obesity","enrollment":50},{"nctId":"NCT06162169","phase":"PHASE1","title":"A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects","status":"COMPLETED","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2023-11-25","conditions":"Healthy Subjects","enrollment":66},{"nctId":"NCT05981365","phase":"PHASE1","title":"Voxelotor CYP and Transporter Cocktail Interaction Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-04-17","conditions":"Sickle Cell Disease","enrollment":44},{"nctId":"NCT05657613","phase":"PHASE1","title":"Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2023-01-03","conditions":"Drug Interactions","enrollment":60},{"nctId":"NCT06105255","phase":"PHASE1","title":"A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553","status":"COMPLETED","sponsor":"InventisBio Co., Ltd","startDate":"2023-05-24","conditions":"Healthy Male","enrollment":45},{"nctId":"NCT03864042","phase":"PHASE1","title":"Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-01-02","conditions":"Advanced Solid Tumors, Metastatic Melanoma","enrollment":56},{"nctId":"NCT06031454","phase":"PHASE1","title":"Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2023-09-01","conditions":"Drug Drug Interaction","enrollment":56},{"nctId":"NCT03720366","phase":"PHASE1","title":"A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-10-04","conditions":"Leukemia, Myeloid, Acute","enrollment":40},{"nctId":"NCT05893849","phase":"","title":"Pharmacokinetics of Clinical Probes and Characteristics of Endogenous Biomarker in Chinese Older Adults","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-03-28","conditions":"Aging","enrollment":624},{"nctId":"NCT05273775","phase":"PHASE1","title":"A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-04-29","conditions":"Chronic Hepatitis B","enrollment":22},{"nctId":"NCT05334108","phase":"PHASE1","title":"Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport","status":"COMPLETED","sponsor":"Emalex Biosciences Inc.","startDate":"2022-04-26","conditions":"Drug Interaction","enrollment":56},{"nctId":"NCT04764851","phase":"PHASE1","title":"Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates","status":"TERMINATED","sponsor":"Emalex Biosciences Inc.","startDate":"2021-02-18","conditions":"Drug-Interactions","enrollment":30},{"nctId":"NCT04233437","phase":"PHASE1","title":"Drug-Drug Interaction Study of MLC1501 Using Cocktail of Drugs Acting as Sensitive Clinical Probes/Substrates of Cytochrome P450 Isoenzymes and Transporters in Healthy Subjects","status":"COMPLETED","sponsor":"Moleac Pte Ltd.","startDate":"2020-02-10","conditions":"Stroke","enrollment":27},{"nctId":"NCT03561298","phase":"PHASE1","title":"A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-06-07","conditions":"Healthy Subjects","enrollment":18},{"nctId":"NCT03363815","phase":"PHASE1","title":"A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-12-04","conditions":"Heathy Volunteer","enrollment":56},{"nctId":"NCT00964106","phase":"PHASE1","title":"Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-26","conditions":"Drug Interactions","enrollment":87},{"nctId":"NCT01489943","phase":"PHASE1","title":"A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-09-19","conditions":"Crohn's Disease","enrollment":24},{"nctId":"NCT00930670","phase":"PHASE4","title":"Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects","status":"COMPLETED","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2009-06","conditions":"Coronary Artery Disease","enrollment":320},{"nctId":"NCT00355615","phase":"PHASE3","title":"PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-07","conditions":"Familial Hypercholesterolemia","enrollment":173}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rosuvastatin-omeprazole","genericName":"Rosuvastatin-omeprazole","companyName":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","companyId":"centre-de-recherche-de-l-institut-universitaire-de-cardiologie-et-de-pneumologie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug reduces cholesterol via HMG-CoA reductase inhibition (rosuvastatin) while simultaneously reducing gastric acid secretion (omeprazole) to protect the gastrointestinal tract. Used for Hypercholesterolemia with elevated cardiovascular risk in patients requiring gastric acid suppression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}